Fineline Cube

Follow:
14422 Articles
Cloudbreak Pharma Profit Highlights Turnaround in Ophthalmic Biotech
Company

Cloudbreak Pharma Profit Highlights Turnaround in Ophthalmic Biotech

Minova Rongzhi Funding Surge: Series B Backed by IDG Capital
CompanyDeals

Minova Rongzhi Funding Surge: Series B Backed by IDG Capital

Walvax Biotechnology Reports 19.5% Revenue Drop, Faces HPV Vaccine Impairment
Company

Walvax Biotechnology Reports 19.5% Revenue Drop, Faces HPV Vaccine Impairment

AbbVie Acquires Bretisilocin from Gilgamesh in $1.2B Deal for MDD Treatment
CompanyDeals

AbbVie Acquires Bretisilocin from Gilgamesh in $1.2B Deal for MDD Treatment

Hengrui Pharmaceuticals Secures NMPA Approval for HRS‑2162 and HRS‑6093 Clinical Trials
CompanyDrug

Hengrui Pharmaceuticals Secures NMPA Approval for HRS‑2162 and HRS‑6093 Clinical Trials

Yichang Humanwell Partners with DP Technology to Leverage Hermite Platform for Drug Discovery
CompanyDeals

Yichang Humanwell Partners with DP Technology to Leverage Hermite Platform for Drug Discovery

Wusheng Erlunbao: Sinopharm’s First‑of‑Its‑Kind Hexavalent Rotavirus Vaccine Receives NMPA Approval
CompanyDrug

Wusheng Erlunbao: Sinopharm’s First‑of‑Its‑Kind Hexavalent Rotavirus Vaccine Receives NMPA Approval

Lepu Medical Secures NMPA Approval for Innovative Sodium Hyaluronate Dermal Filler
CompanyMedical Device

Lepu Medical Secures NMPA Approval for Innovative Sodium Hyaluronate Dermal Filler

InxMed Secures HK$100 M Private Placement from TruMed Health
CompanyDeals

InxMed Secures HK$100 M Private Placement from TruMed Health

Chengdu Ucello’s UC101 CAR‑T Gains NMPA Approval
CompanyDrug

Chengdu Ucello’s UC101 CAR‑T Gains NMPA Approval

Henlius, Serplulimab and Abbott Drive Robust 2025 Financials
Company

Henlius, Serplulimab and Abbott Drive Robust 2025 Financials

BeOne Secures $950 M Deal with Royalty Pharma for Tarlatamab Rights
CompanyDeals

BeOne Secures $950 M Deal with Royalty Pharma for Tarlatamab Rights